Savings & Support Resources

See how you may be able to save on Retevmo and get support along the way

Retevmo Savings Card

Eligible commercially insured covered patients may pay as little as $0 a month^*

Governmental beneficiaries excluded, terms and conditions apply

Paying for treatment shouldn’t be an additional concern for you and your loved ones, so we’ve created the Retevmo Savings Card, which may help you manage treatment costs.

Need a Savings Card?

Download Savings Card

^*Offer good for up to 12 months. Patients must have coverage for Retevmo through their commercial drug insurance coverage to pay as little as $0 for a 30-day supply of Retevmo. Offer subject to a monthly cap and a separate annual cap of $25,000. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for Patients without commercial drug insurance or whose prescription claims for Retevmo are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any State Patient or Pharmaceutical Assistance Program. Offer void where prohibited by law and subject to change or discontinue without notice. Subject to additional terms and conditions.

TRICARE^® is a registered trademark of the Department of Defense (DoD), DHA.

Retevmo Ongoing Support

Starting a new cancer therapy can be overwhelming. Whether you have questions about your Retevmo prescription or are looking for some additional support starting treatment, The Lilly Oncology Support Center is here for you. Call 1-866-472-8663 to connect with an agent who may be able to help.

Filling your prescription

There are multiple ways to get Retevmo, depending on your insurance. You may receive your medication from your hospital, your doctor, or from a specialty pharmacy.

Here’s how a specialty pharmacy works with you to fill your Retevmo prescription:

Your doctor sends your prescription to a specialty pharmacy
The specialty pharmacy will call you to schedule a date and time to deliver your Retevmo medication (you may not recognize the phone number)
The specialty pharmacy can also help assess your eligibility for the Retevmo Savings Card^†

^†This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program. Terms and conditions apply for eligible patients.

The Lilly Oncology Support Center can help you find the specialty pharmacy with the lowest out-of-pocket cost

Learn more about Retevmo

See how Retevmo works, how to take it, and some side effects you may experience with treatment. Download the brochure below.

Download the Patient Brochure – Thyroid (PDF) Download the Patient Brochure – Lung (PDF) Download the Patient Brochure – Other Cancers (PDF)

Hear a real story from a real patient taking Retevmo

Support groups

Connect with others in your community who understand your diagnosis

You are not alone on this cancer journey. There are organizations that can connect you with opportunities and support.^‡

American Lung Association^® is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. The Lung Association is committed to defeating lung cancer and supporting those affected by it.

GO2 Foundation for Lung Cancer^® transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

The Happy Lungs Project is patient driven 501c3 public charity committed to supporting researchers and clinicians in their work toward finding a cure for RET Positive Non-Small Cell Lung Cancer, while providing helpful information to empower patients in their own healing and journey.

LUNGevity Foundation^®, the nation's leading lung cancer-focused nonprofit, is committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease.

Founded by survivors and caregivers of those impacted by RET-driven cancers, RETpositive aims to build hope, resources and a sense of community for RET-positive cancer patients. By sharing emotional support and knowledge of the latest treatment options and current RET specific research, RETpositive hopes to increase both quality of life and life expectancy for those impacted by RET-driven malignancies.

The THANC (Thyroid, Head and Neck Cancer) Foundation is an international, independent nonprofit dedicated to supporting research and education in the early detection and treatment of thyroid, head and neck cancers. THANC is actively committed to advancing new therapies and alleviating the suffering and functional impairment of patients who undergo treatment. The THANC Guide is a significant resource that endeavors to help patients through their cancer journey.

ThyCa: Thyroid Cancer Survivors’ Association, Inc., an international nonprofit organization advised by thyroid cancer specialists, educates and supports patients and families through its comprehensive website, support groups, person-to-person support, free newsletter and downloadable handbooks and low-iodine cookbook, available in numerous languages. ThyCa sponsors seminars, workshops, and an annual international 3-day conference, as well as Thyroid Cancer Awareness Month, year-round awareness programs for early detection, and thyroid cancer research funds and research grants.

^‡This information has been provided by the listed organizations, and Lilly is not responsible for the content. Its use on this site is not intended to serve as an endorsement of the listed organizations. All third-party organization names and other trademarks are the property of their respective trademark owners. Those trademark owners are not affiliated with Lilly and they do not sponsor or endorse this material.

WARNINGS

RETEVMO may cause serious side effects, including:

Liver problems: Liver problems (higher levels of liver enzymes) are common with RETEVMO and may sometimes be serious. Your doctor will do blood tests before and during treatment with RETEVMO to check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems during treatment:

yellowing of your skin or the white part of your eyes (jaundice)
dark, “tea-colored” urine
sleepiness
bleeding or bruising

loss of appetite
nausea or vomiting
pain on the upper right side of your stomach area

Lung problems: RETEVMO may cause severe or life-threatening inflammation (swelling) of the lungs during treatment, that can lead to death. Tell your doctor right away if you get any new or worsening lung symptoms, including:

shortness of breath

cough

fever

High blood pressure (hypertension): High blood pressure is common with RETEVMO. It may sometimes be severe. You should check your blood pressure regularly during treatment with RETEVMO. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure. Tell your doctor if you have increased blood pressure readings or get any symptoms of high blood pressure, including:

confusion
headaches
shortness of breath

dizziness
chest pain

Heart rhythm changes (QT prolongation). RETEVMO may cause very slow, very fast, or irregular heartbeats. Your healthcare provider may perform tests before and during treatment with RETEVMO to check the activity of your heart and the levels of body salts (electrolytes) and thyroid-stimulating hormone (TSH) in your blood. Tell your doctor right away if you get any of the following symptoms:

loss of consciousness
fainting
dizziness

a change in the way your heart beats (heart palpitations)

Bleeding problems: RETEVMO can cause bleeding, which can be serious and may lead to death. Tell your doctor if you have any signs of bleeding during treatment, including:

vomiting blood or if your vomit looks like coffee-grounds
pink or brown urine
red or black stools that look like tar
coughing up blood or blood clots
unusual bleeding or bruising of your skin
menstrual bleeding that is heavier than normal

unusual vaginal bleeding
nose bleeds that happen often
drowsiness or difficulty being awakened
confusion
headache
change in speech

Allergic reactions: RETEVMO can cause a fever, rash, or pain in muscles or joints, especially during the first month of treatment. Tell your doctor if you get any of these symptoms.

Tumor lysis syndrome (TLS): TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, an abnormal heartbeat, and can lead to hospitalization. Your healthcare provider may do blood tests to check you for TLS. You should stay well hydrated during treatment with RETEVMO. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with RETEVMO:

nausea
vomiting
weakness
swelling

shortness of breath
muscle cramps
seizures

Risk of wound healing problems: Wounds may not heal well during treatment with RETEVMO. Tell your doctor if you plan to have any surgery before or during treatment with RETEVMO.

You should stop taking RETEVMO at least 7 days before planned surgery.
Your doctor should tell you when you may start taking RETEVMO again after surgery.

Low thyroid hormone levels in your blood (hypothyroidism). Your healthcare provider will do blood tests to check your thyroid function before and during treatment with RETEVMO. Tell your healthcare provider right away if you develop signs or symptoms of low thyroid hormone levels, including:

weight gain
feeling cold

tiredness that worsens or does not go away
constipation

Common side effects

The most common side effects of RETEVMO are:

swelling of your arms, legs, hands, and feet (edema)
diarrhea
tiredness
dry mouth
high blood pressure

stomach-area (abdominal) pain
constipation
rash
nausea
headache

The most common severe abnormal laboratory test results with RETEVMO include decreased white blood cell count, increased liver enzymes, decreased levels of sodium in the blood, and decreased levels of calcium in the blood.

RETEVMO may affect the ability to have children for both females and males. Talk to your doctor if you want to have children and you are thinking about starting treatment with RETEVMO.

RETEVMO can harm your unborn baby. You should not become pregnant during treatment with RETEVMO.
If you are able to become pregnant:
- Your doctor will do a pregnancy test before you start treatment with RETEVMO.
- You should use effective birth control (contraception) during treatment and for 1 week after your last dose of RETEVMO. Talk to your doctor about birth control methods that may be right for you.
- Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with RETEVMO.
Males with partners who are able to become pregnant should use effective birth control during treatment with RETEVMO and for 1 week after your last dose of RETEVMO.

These are not all the possible side effects with RETEVMO. If you are concerned about side effects, talk to your doctor. Tell your doctor about any side effects you have. You can also report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before taking RETEVMO, tell your doctor about all your medical conditions, including if you:

have liver problems
have lung or breathing problems other than lung cancer
have high blood pressure
have heart problems, including a condition called QT prolongation
have bleeding problems
plan to have surgery. You should stop taking RETEVMO at least 7 days before your planned surgery.
are pregnant or plan to become pregnant. See section above for additional information.
are breastfeeding or plan to breastfeed. It is not known if RETEVMO passes into your breast milk. Do not breastfeed during treatment with RETEVMO and for 1 week after your last dose.

Also tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RETEVMO may affect the way other medicines work and other medicines may affect how RETEVMO works, and may increase your risk of side effects.

You should avoid taking certain medicines when also taking RETEVMO. These include:
- St. John’s wort,
- proton-pump inhibitors (PPIs) such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, and rabeprazole,
- H2 blockers such as famotidine, nizatidine, and cimetidine,
- antacids that contain aluminum, magnesium, calcium, simethicone, or buffered medicines.

If you cannot avoid taking PPIs, H2 blockers, or antacids, see the “How to take with certain other medicines” section below for more information. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How to take RETEVMO

Take RETEVMO exactly as your doctor tells you.
Your doctor may change your dose, temporarily stop, or permanently stop treatment with RETEVMO if you have side effects. Do not change your dose or stop taking RETEVMO unless your doctor tells you.
Swallow RETEVMO capsules whole. Do not crush or chew the capsules.
RETEVMO is taken by mouth, usually 2 times a day, about 12 hours apart.
Take RETEVMO with or without food.
If you vomit after taking a dose of RETEVMO, do not take an extra dose. Take the next dose of RETEVMO at your scheduled time.
Do not take a missed dose of RETEVMO unless it is more than 6 hours until your next scheduled dose.
If you take too much RETEVMO, call your doctor or go to the nearest hospital emergency room right away.

How to take RETEVMO with certain other medicines

If you take a PPI (such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, or rabeprazole), take RETEVMO with food.
If you take an antacid that contains aluminum, magnesium, calcium, simethicone, or buffered medicines, take RETEVMO 2 hours before or 2 hours after taking the antacid.
If you take an H2 blocker (such as famotidine, nizatidine, or cimetidine), take RETEVMO 2 hours before or 10 hours after taking the H2 blocker.

Learn more

RETEVMO is a prescription medicine. For more information, call 1-800-545-5979.

This summary provides basic information about RETEVMO. It does not include all information known about this medicine. Read the information that comes with your medicine each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other health care provider about RETEVMO and how to take it. Your doctor is the best person to help you decide if RETEVMO is right for you.

SE CON BS ALL 21SEP2022

RETEVMO^® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

RETEVMO^® (reh-TEHV-moh) is used to treat certain cancers caused by abnormal RET genes in:

adults with locally advanced non-small cell lung cancer (NSCLC) or NSCLC that has spread.
adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who require a medicine by mouth or injection (systemic therapy).^*
adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy), and who have received radioactive iodine and it did not work or is no longer working.^*
adults with locally advanced solid tumors (cancers) or solid tumors that have spread, and have gotten worse (progressed) on or after other treatment or there are no satisfactory treatment options.^*

Your doctor will perform a test to make sure that RETEVMO is right for you.

It is not known if RETEVMO is safe and effective when used:

in children younger than 12 years of age for the treatment of MTC who require systemic therapy, and advanced thyroid cancer who require systemic therapy and who have received radioactive iodine and it did not work or is no longer working, or
in children for the treatment of any other cancers.

^* This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit of Retevmo for this use.